Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Anixa Biosciences, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, in New York City [1][2] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [2] - The company utilizes a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by using the natural ligand of the FSHR receptor, FSH, to bind to tumor cells [2] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [2] - The vaccines are based on immunizing against "retired" proteins expressed in certain cancer forms, with Cleveland Clinic entitled to royalties and commercialization revenues from these technologies [2] - Anixa's business model involves partnerships with renowned research institutions at all development stages, allowing the company to explore emerging technologies for further development and commercialization [2]